Histopathological Study of Human Cisplatin Nephropathy

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Toxicologic pathology (Print)

• Publication date

  1986-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/019262338601400215PMID 3764321
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin.

  1984cited by this paper
• Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid.

  1984cited by this paper
• Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives.

  1984cited by this paper
• Lectin binding sites in kidney. A comparative study of 14 animal species.

  1983cited by this paper
• [Case of cisplatin induced acute renal failure].

  1983cited by this paper
• Lectin binding sites in kidney. A comparative study of 14 animal species.

  1983cited by this paper
• Experimental ultrastructural and X-ray microanalysis study of cisplatin in the rat: intracellular localization of platinum.

  1982cited by this paper
• Severe nephrotoxicity: a probable complication of cis-dichlorodiammineplatinum (II) and cephalothin-gentamicin therapy.

  1982cited by this paper
• The renal toxicity of cancer chemotherapeutic agents.

  1982cited by this paper
• Cis-diamminedichlorplatinum-induced acute renal failure in the rat.

  1982cited by this paper
• Clinical kinetics on intact cisplatin and some related species.

  1981cited by this paper
• Acute and chronic cisplatin nephropathy in rats.

  1981cited by this paper
• Platinosomes produced in cultured cells by platinum coordination complexes.

  1981cited by this paper
• Clinical kinetics of intact cisplatin and some related species

  1981cited by this paper
• Acute and chronic cisplatin nephropathy in rats.

  1981cited by this paper
• Platinosomes produced in cultured cells by platinum coordination complexes.

  1981cited by this paper
• Renal handling of cis-diamminedichloroplatinum(II).

  1980cited by this paper
• CISPLATIN NEPHROTOXICITY: THE EFFECT OF DOSE, SCHEDULE, AND HYDRATION SCHEME

  1980cited by this paper
• Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations.

  1980cited by this paper
• Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid.

  1979cited by this paper
• Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid.

  1979cited by this paper
• Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic millieu.

  1979cited by this paper
• Long term effect of Cis‐Diamminedichloride platinum (CDDP) on renal function and structure in man

  1978cited by this paper
• Acute renal failure after cis-dichlorodiammineplatinum(II) and gentamicin-cephalothin therapies.

  1978cited by this paper
• The renal pathology in clinical trials of Cis‐platinum (II) diamminedichloride

  1977cited by this paper
• Cis-dichlorodiammineplatinum(II) in advanced bladder cancer.

  1976cited by this paper
• Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs.

  1976cited by this paper
• Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in combination with cyclophosphamide (NSC-26271) in the treatment of human malignancies.

  1975cited by this paper
• Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in combination with cyclophosphamide (NSC-26271) in the treatment of human malignancies.

  1975cited by this paper
• Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases.

  1975cited by this paper
• Platinum nephrotoxicity

  1974cited by this paper
• Clinical and pharmacological studies with cis-diamminedichloroplatinum (II).

  1973cited by this paper

• Rodent models of AKI and AKI-CKD transition: an update in 2024.

  2024cites this paper
• Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC).

  2024cites this paper
• Cisplatin-based combination therapy for cancer

  2023cites this paper
• Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

  2023cites this paper
• Physiologically-Based Modeling and Interspecies Prediction of Cisplatin Pharmacokinetics.

  2023cites this paper
• Valproic acid treatment attenuates cisplatin‐induced kidney injury by suppressing proximal tubular cell damage

  2023cites this paper
• Molecular Mechanisms and Biomarkers Associated with Chemotherapy-Induced AKI

  2022cites this paper
• Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy

  2021cites this paper
• Cisplatin-induced renal toxicity in elderly people

  2020cites this paper
• Evaluation of 10 Urinary Biomarkers for Renal Safety With 5 Nephrotoxicants in Nonhuman Primates

  2020cites this paper
• A suspected case of drug-induced tubulointerstitial nephritis by pilocarpine hydrochloride

  2019cites this paper
• Cisplatin-Induced Rodent Model of Kidney Injury: Characteristics and Challenges

  2018cites this paper
• Cisplatin nephrotoxicity: a review of the literature

  2018cites this paper
• Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors

  2018cites this paper
• Critical review of renal tubule karyomegaly in non-clinical safety evaluation studies and its significance for human risk assessment

  2018cites this paper
• EFFECT OF CHRONOMODULATED ARTESUNATE ON RENAL AND HAEMATOLOGICAL TOXICITY IN CISPLATIN-TREATED WISTAR RATS

  2017cites this paper
• Chemopreventive Effect of Tadalafil in Cisplatin-Induced Nephrotoxicity in Rats.

  2016cites this paper
• Bridging translation for acute kidney injury with better preclinical modeling of human disease.

  2016cites this paper
• Recent Successes in the Identification, Development, and Qualification of Translational Biomarkers

  2015cites this paper
• Comparison between the effects of one-day treatment regimen with cisplatin on renal function and various biochemical parameters in patients with gastric and lung cancer compared with two-days divided cisplatin treatment regimen

  2015cites this paper
• Long-term Morbidity of Testicular Cancer Treatment.

  2015cites this paper
• The renoprotective effect of curcumin in cisplatin-induced nephrotoxicity

  2015cites this paper
• Antioxidant and Protective Effects of Vitex negundo against Cisplatin induced Nephrotoxicity in Male Albino Rats

  2015cites this paper
• Histological Study of Toxic Effects of Cisplatin Single Dose Injection on Rat Kidney

  2014cites this paper
• Protective Effects of Hydroalcoholic Extract of Boerhaavia Diffusa Linn Against Cisplatin Induced Nephrotoxicity in Rats

  2014cites this paper
• Carvedilol efficiently protects kidneys without affecting the antitumor efficacy of cisplatin in mice.

  2013cites this paper
• Chapter 10 – Urinary Tract

  2012cites this paper
• T-2 toxin induces apoptosis in differentiated murine embryonic stem cells through reactive oxygen species-mediated mitochondrial pathway

  2012cites this paper
• Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up.

  2012cites this paper
• Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N

  2011cites this paper
• Testicular cancer survivorship: research strategies and recommendations.

  2010cites this paper
• Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase

  2010cites this paper
• Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.

  2010cites this paper
• Fluid and diuretic therapy for preventing cisplatin‐induced nephrotoxicity

  2008cites this paper
• Cisplatin Nephrotoxicity: A Review

  2007cites this paper
• Comparative analysis of gene expression between renal cortex and papilla in nedaplatin-induced nephrotoxicity in rats

  2007cites this paper
• 10 – Urinary Tract

  2007cites this paper
• Long-term studies of cisplatin-induced reductions in porcine renal functional reserve

  2004cites this paper
• Cisplatin-induced reductions in renal functional reserve uncovered by unilateral nephrectomy: an experimental study in the pig

  2004cites this paper
• Kidney Slices of Human and Rat to Characterize Cisplatin-Induced Injury on Cellular Pathways and Morphology

  2004cites this paper
• Use of cultured cells of kidney origin to assess specific cytotoxic effects of nephrotoxins.

  2003cites this paper
• IX – Urinary Tract

  2000cites this paper
• Embryotoxic effects of SKI 2053R, a new potential anticancer agent, in rats.

  1998cites this paper
• Complications in the Oncological Patient

  1996cites this paper
• Experimental maxillofacial arterial chemoembolization with encased-cisplatin ethylcellulose microspheres.

  1995cites this paper
• Toxicity of cis-diamminedichloroplatinum (II) (cisplatin) in the frog, Rana pipiens.

  1990cites this paper
• The impact of hydronephrosis on renal function in patients treated with cisplatin‐based chemotherapy for metastatic nonseminomatous germ cell tumors

  1988cites this paper
• Effects of cis-diamminedichloroplatinum(II) on rabbit kidney in vivo and on rabbit renal proximal tubule cells in culture.

  1988cites this paper
• Nephrotoxicity screening in rats: a validation study

  1988cites this paper
• Principles and methods for the assessment of neurotoxicity associated with exposure to chemicals

  1986cites this paper
• ethylcellulose microspheres. chemoembolization with encased-cisplatin Experimental maxillofacial arterial

  year unknowncites this paper